J&J hopes Ottava will boost its standing in the growing surgical robotics market, which is currently dominated by Intuitive Surgical.

Takeda’s TAK-881-3001 pivotal Phase II/III clinical trial of TAK-881 in patients with PID has met its primary endpoint.

Mirum Pharmaceuticals has reported that its VISTAS Phase IIb clinical study of volixibat has achieved its primary goal in patients with PSC.

Celcuity has reported topline outcomes from the PIK3CA mutant cohort of the Phase III VIKTORIA-1 clinical trial assessing gedatolisib combined with fulvestrant, with or without palbociclib, in ...

Lakewood-Amedex Biotherapeutics has announced promising data on AMR for its lead compound, Nu-3, which is being developed as a topical treatment for iDFU.

Martin Makary, commissioner of the Food and Drug Administration (FDA) announces plans to cut the time it takes drug companies to test new medicines by getting more visibility into clinical trials as ...

Google Ventures-backed Iterative will now expand its platform into burgeoning therapeutic areas like cardiology and obesity.

Argo Biopharma has dosed the first subject in its Phase I clinical trial assessing BW-50218, a siRNA therapeutic targeting the TTR protein.

After two years, there was an 87% reduction in death in ALS patients treated with Corcept's dazucorilant compared with those who received placebo.

Bambusa Therapeutics has completed patient enrolment in its Phase Ib/IIa trial evaluating BBT001 to treat moderate-to-severe atopic dermatitis.

Massive Bio and OpenAI are to expand access to clinical studies via AI-driven protocol parameterisation and real-time patient pre-screening.

Ahead of Biomed Israel, Ittai Harel highlights a growing cohort of companies leveraging AI and data science tools to revolutionise clinical research.